On November 4, "Juzi Bio," a portfolio company of HeYi ChenKun-managed fund-of-funds and invested in by Black Ant Capital, officially listed on the Hong Kong Stock Exchange under the stock code: 2367.HK.

Founded in 2000, Juzi Bio is China's leading company specializing in professional skincare products based on bioactive ingredients. Its core technological advantage lies in its ability to independently research, develop, and produce recombinant collagen and highly active rare ginseng saponins—capabilities that keep it at the forefront globally. Juzi Bio not only became one of the first companies to achieve mass production of recombinant collagen but also boasts one of the highest production capacities for both recombinant collagen and rare ginseng saponins worldwide.

Currently, Juzi Bio has established eight major brands—Ke Fumei, Ke Lijin, Ke Yu, Ke Hen, Ke Fuping, Li Yan, Xin Gan, and Shen Gan—which cover functional skincare products, medical dressings, and health supplements. The company boasts a product portfolio of 105 SKUs and maintains a pipeline of 103 products currently in development.

Giant Bio leverages synthetic biology technology to produce recombinant collagen, encompassing key processes such as gene recombination, cell-factory construction, fermentation, and downstream separation and purification. As a cutting-edge field in biotechnology, synthetic biology enhances the safety, stability, and biological activity of bioactive ingredients—transforming the beauty and health sectors from the ground up. Currently, Giant Bio has established a robust synthetic biology platform that integrates interdisciplinary research in biotechnology, biochemistry, and bioengineering, backed by years of industry expertise. The company also holds 79 granted and pending patents. Supported by this advanced technology platform, Giant Bio has successfully developed and scaled up the production of 33 distinct types of recombinant collagen to date.

The funds raised from this Hong Kong listing will be used for conventional purposes such as R&D investments, team recruitment, as well as expanding the production of recombinant collagen and ginseng saponins.